Pre-Transplant Hyperparathyroidism and Graft or Patient Outcomes After Kidney Transplantation
Transplant International · 2024
DOI: 10.3389/ti.2024.11916 ↗Kurz gefasst
Fachartikel in der Zeitschrift Transplant International, 2024. Verfasst von Fernanda Guedes Rodrigues und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology, Department of Internal Medicine, University Medical Center Groningen, University of Groningen, Groningen, Netherlands. Hauptthemen laut MEDLINE: Kidney Transplantation, Hyperparathyroidism. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The impact of pre-transplant parathyroid hormone (PTH) levels on early or long-term kidney function after kidney transplantation is subject of debate. We assessed whether severe hyperparathyroidism is associated with delayed graft function (DGF), death-censored graft failure (DCGF), or all-cause mortality. In this single-center cohort study, we studied the relationship between PTH and other parameters related to bone and mineral metabolism, including serum alkaline phosphatase (ALP) at time of transplantation with the subsequent risk of DGF, DCGF and all-cause mortality using multivariable logistic and Cox regression analyses. In 1,576 kidney transplant recipients (51.6 ± 14.0 years, 57.3% male), severe hyperparathyroidism characterized by pre-transplant PTH ≥771 pg/mL (>9 times the upper limit) was present in 121 patients. During 5.2 [0.2–30.0] years follow-up, 278 (15.7%) patients developed DGF, 150 (9.9%) DCGF and 432 (28.6%) died. A higher pre-transplant PTH was not associated with DGF (HR 1.06 [0.90–1.25]), DCGF (HR 0.98 [0.87–1.13]), or all-cause mortality (HR 1.02 [0.93–1.11]). Results were consistent in sensitivity analyses. The same applied to other parameters related to bone and mineral metabolism, including ALP. Severe pre-transplant hyperparathyroidism was not associated with an increased risk of DGF, DCGF or all-cause mortality, not supporting the need of correction before kidney transplantation to improve graft or patient survival.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Nephrology, Department of Internal Medicine, University Medical Center Groningen, University of Groningen, Groningen, Netherlands.
- Nutrition Post Graduation Program, Universidade Federal de São Paulo (UNIFESP), São Paulo, Brazil.
- Department of Surgery, Division of Surgical Oncology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands.
- Department of Surgery, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands.
- Department of Endocrinology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands.
- Department of Surgery, Martini Hospital Groningen, Groningen, Netherlands.
Zitieren
APA
Rodrigues, F. G., Van Der Plas, W. Y., Sotomayor, C. G., Van Der Vaart, A., Kremer, D., Pol, R. A., Kruijff, S., Heilberg, I. P., Bakker, S. J. L., TransplantLines Investigators, & De Borst, M. H. (2024). Pre-Transplant Hyperparathyroidism and Graft or Patient Outcomes After Kidney Transplantation. Transplant International. https://doi.org/10.3389/ti.2024.11916
Vancouver
Rodrigues FG, Van Der Plas WY, Sotomayor CG, Van Der Vaart A, Kremer D, Pol RA, et al. Pre-Transplant Hyperparathyroidism and Graft or Patient Outcomes After Kidney Transplantation. Transplant International. 2024. doi:10.3389/ti.2024.11916
BibTeX
@article{Rodrigues2024,
author = {Rodrigues, Fernanda Guedes and Van Der Plas, Willemijn Y and Sotomayor, Camilo German and Van Der Vaart, Amarens and Kremer, Daan and Pol, Robert A and Kruijff, Schelto and Heilberg, Ita Pfeferman and Bakker, Stephan J L and TransplantLines Investigators, TransplantLines Investigators and De Borst, Martin H},
title = {Pre-Transplant Hyperparathyroidism and Graft or Patient Outcomes After Kidney Transplantation},
journal = {Transplant International},
year = {2024},
doi = {10.3389/ti.2024.11916}
}
EUVIMED